E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Become a Fan

« NIH Releases New Stem Cell Rules | Main | WIPO Becomes Priority Document Exchange Participant Office »

July 07, 2009

Comments

lexapro (escitalopram) and celexa (citalopram) are forest/lundbeck drugs, not infosint drugs.

Dear [correction]:

Thank you for catching the error in the post. The post has been revised to reflect the correct identity of the drug manufacturers.

Suresh

If what the complaint says is true, Stanford really effed this up.

The increased focus of universities to develop and market IP has led to lawsuits like this and extended litigation. Companies have modified themselves to be more adaptive to this unique sector (see http://www.prweb.com/releases/2009/07/prweb2594164.htm). This may ultimately benefit the US consumer because as universities profit from their research they can invest more into it.

The comments to this entry are closed.

August 2016

Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31